Navigation Links
GENova gains access to Big Pharma
Date:9/15/2009

NEW YORK, NY, Sept. 15 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova"), a cancer drug acquisition and development company, is pleased to announce it has gained access to distribution channels for its promising drug targets through a recently-signed deal with Bridge BioResearch Plc. ("Bridge BioResearch"). GENova expects to generate licensing fees and royalties from the out-licensed manufacturing and marketing rights to leading pharmaceutical companies to exceed more than 5% in a market currently valued at $3billion+ a year over the following 15-20 years which is the duration of the patents.

Bridge BioResearch is an international drug discovery company that focuses on metabolic disorders, and has well-established distribution channels and relationships with leading pharmaceutical companies.

Through a recent collaboration deal, the two companies are working together to leverage their respective Research and Development partners and distribution channels worldwide, with the mutual goal of developing their proprietary drug targets with the utmost cost and time efficiency.

The two companies are both in the business of acquiring early-stage developmental drugs, out-licensing them for development and commercialization, and garnering royalty payments in the process. GENova's focus is oncology, while Bridge BioResearch specializes in Obesity and Type 2 Diabetes drugs. Both companies share a mutual goal of fast-tracking their target drugs through development, clinical studies, licensing to Big Pharma such as Biogen, Elan, Merck's and Genentech.

"This reciprocal arrangement is a huge benefit to both companies," says Aaron Whiteman, CEO for GENova. "I am confident that with our new access to Big Pharma distribution channels we can usher our promising patents through the development process as expeditiously as possible, and ultimately start reaping royalty payments sooner than ever foreseen."


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GENova names Aaron Whiteman as CEO
2. GENova names Dr. John Savin as Vice President
3. Genova files patent for new prostate cancer treatment
4. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
5. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
6. GENova appoints Director of Asian business development
7. GENova files patent for new breast cancer treatment
8. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
9. GENova issues clarifying press release
10. GENova appoints Dr. Philip Gould to Scientific Advisory Board
11. GENova appoints Dr. Wang Chong to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... (PRWEB) August 20, 2014 Recently, iFitDress.com,a ... occasion outfits, has unveiled its new collection of ... made to expand the company’s global market. Each item ... to the company’s senior spokesman, customers that have specific ... at iFitDress.com. Now, all the brand new items are ...
(Date:8/19/2014)... Aug. 19, 2014 (HealthDay News) -- Lupus and ... as headaches and seizures, which can delay a ... Treatments for rheumatic diseases can also cause ... Loyola University Medical Center in Maywood, Ill. ... the joints and soft tissues, such as lupus, ...
(Date:8/19/2014)... Just back from Glasgow where he helped distribute thousands ... Commonwealth Games (July 23 – August 6), Pete Dwan is ... And the need for his work cannot be overstated. , ... 59 consumed Class A drugs within the last year. And ... (NPS) drugs considered to be “legal highs” until June 2014, ...
(Date:8/19/2014)... Warfarin, the longtime standard treatment for atrial fibrillation, ... anticoagulant drug marketplace including dabigatran, rivaroxaban, and apixaban. ... these novel oral anticoagulants (NOACs) into clinical practice. ... new anticoagulant prescriptions yet this represents 98% of ... The American Journal of Medicine . , ...
(Date:8/19/2014)... City, Utah (PRWEB) August 19, 2014 ... Benefits Solution, published a new guide on compliance ... Zane Benefits, small businesses want to offer employee ... health insurance is unsustainable. Additionally, there are new ... portability, guaranteed-issue, and lower costs. , The ...
Breaking Medicine News(10 mins):Health News:Discounted Pewter Evening Dresses For 2014 Unveiled By Company iFitDress.com 2Health News:Certain Symptoms Can Delay Lupus Diagnosis, Researchers Report 2Health News:British Scientologist on a Mission to Save Youth from Drug Abuse 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 3
... medications is associated with increased severity of erectile dysfunction, according ... British Journal of Urology International ., This study surveyed 37,712 ... taking various medications are likely to have more severe ED. ... multiethnic cohort of men ages 46 to 69 who are ...
... NJ . November 13, 2011. Kessler Foundation received a ... Geriatric Life Improvement. Anna Barrett, MD, director of Stroke ... to finding better ways to treat hidden disabilities that ... are pleased to receive this grant," said Rodger DeRose, ...
... By Serena Gordon HealthDay Reporter , MONDAY, Nov. ... warfarin need blood tests every four weeks to make sure ... suggests that some people could safely have those tests done ... isn,t an option for everyone on warfarin, just those who ...
... News) -- Drinking alcohol may be especially risky for young ... including having mothers, grandmothers or aunts with the disease, a ... Medicine in St. Louis examined data on more than 9,000 ... aged 9 to 15) through 2007. They focused on ...
... Indianapolis Wishard Health Services chief medical information officer, ... named one of America,s leading clinical informaticists by Modern ... Dr. Dexter is an associate professor of clinical medicine ... director of clinical applications at Wishard. "Dr. ...
... MONDAY, Nov. 14 (HealthDay News) -- Hearing loss affects ... far higher number than previously believed, researchers report. ... during National Health and Nutritional Examination Surveys (NHANES) from ... Organization,s definition of hearing loss (unable to hear sounds ...
Cached Medicine News:Health News:Erectile dysfunction increases with use of multiple medications 2Health News:Erectile dysfunction increases with use of multiple medications 3Health News:Kessler Foundation awarded stroke research grant by Wallerstein Foundation 2Health News:Warfarin May Need Less Monitoring for Some 2Health News:Warfarin May Need Less Monitoring for Some 3Health News:Drinking Risky for Women With Family History of Breast Cancer: Study 2Health News:Drinking Risky for Women With Family History of Breast Cancer: Study 3Health News:Indianapolis doc recognized as one of nation's top health info tech experts 2Health News:Indianapolis doc recognized as one of nation's top health info tech experts 3Health News:Hearing Loss Far More Common Than Expected 2
(Date:8/19/2014)... 19, 2014 According to Kalorama Information, electronic ... make Big Data in healthcare a reality, and this ... of the American Recovery and Reinvestment Act, the U.S. ... projects and penalties will start applying soon for use ... its complete study of the EMR industry, EMR ...
(Date:8/19/2014)... , Aug. 19, 2014  Regeneron Pharmaceuticals, Inc. (NASDAQ: ... conferences: , Sanofi and Regeneron will host an IR ... on Tuesday, September 2, 2014 , Baird 2014 ... September 3, 2014 , Citi,s 9 th ... Thursday, September 4, 2014 , Morgan Stanley Global ...
(Date:8/19/2014)... PARK, Calif. , Aug. 19, 2014   DelMar ... a protocol amendment to allow for expanded dosing in its ... and Drug Administration (FDA) and that a new cohort of ... clinical trial sites in the United States ... million have been raised through warrant exercise in two separate ...
Breaking Medicine Technology:Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7
... YORK, Nov. 17 Romeo and Juliette Laser ... hair removal center in New York City to own the ... leading developer and manufacturer of laser and light-based aesthetic treatment ... patented MultiPlex sequencing technology, is a highly versatile laser aesthetic ...
... , NEW YORK, Nov. 17 Engineer/pilot/attorney ... credit. They include technology that thwarts piracy in ... behind, devices to enhance airport security and even an ... interests that they have, indeed, found their match. ...
Cached Medicine Technology:Romeo and Juliette Laser Hair Removal Is First Center in New York City to Own Cynosure's New Elite MPX(TM) Laser System 2When Viruses (Including H1N1) and Bacteria are as Close as your Fingertips; VirWall's New Innovation Can Disarm Killer Keyboards 2
The ACMI TurboFlow 18 L and 10 L Insufflators provide rapid distention for all laparoscopic procedures. Eleven built-in safety features make insufflation reliable and dependable....
This multiple-function instrument allows the surgeon to grasp, coagulate, and transect tissue with a single instrument, eliminating the need for multiple instruments and, in some procedures, costly l...
Bipolar forceps...
... An in vitro Nucleic Acid ... using Microplate Chemiluminescence for the ... (HPV) Types 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 ... Lowand High-Risk Groups in Cervical ...
Medicine Products: